What Is Oligoprogression and How Is It Treated?

Oligoprogression is a pattern of cancer behavior in which only a small number of tumors start growing again while a patient’s overall disease remains controlled by systemic treatment such as targeted therapy or immunotherapy. Rather than the cancer rebelling everywhere at once, just a few “rogue” spots break through. The concept matters because it opens the door to treating those few growing lesions directly, often with highly focused radiation, instead of abandoning a drug regimen that is still working everywhere else. The idea has reshaped how oncologists think about progression, turning what used to be an automatic signal to switch treatments into a more nuanced decision.

How Oligoprogression Differs From Widespread Progression

In traditional oncology thinking, cancer progression was treated as an all-or-nothing event. If imaging showed growth anywhere, the assumption was that the current therapy had failed, and it was time to move to the next line of treatment. Oligoprogression challenges that assumption. It is generally defined as progression in a limited number of metastatic sites, usually three to five, while the patient is on or has recently been on systemic therapy, with the rest of the disease remaining stable or responding.

¹

The distinction is clinically important because a patient whose cancer is growing in only one or two spots likely has a very different biological situation than a patient whose disease is progressing everywhere. Research using circulating tumor DNA and molecular profiling has shown that oligoprogression under ongoing systemic therapy often reflects spatially constrained resistance, meaning a small cluster of cancer cells has developed a way around the drug, while the rest of the disease has not. This is different from systemic molecular escape, where resistance mechanisms have spread broadly and the drug is no longer useful anywhere.

²

Why It Happens More Often Now

Oligoprogression was not a common clinical observation in the era of older chemotherapy drugs. Those regimens tended to either work broadly or fail broadly. The explosion of targeted therapies and immunotherapies over the past two decades has changed the landscape. Drugs that precisely target a mutation in lung cancer, or checkpoint inhibitors that unleash the immune system against melanoma or kidney cancer, often produce long periods of disease control. But cancer is not one uniform mass. Individual tumors within the same patient can have slightly different genetics, and eventually one or two of those tumors may acquire a new mutation that lets them resist the drug while everything else stays suppressed. Modern systemic therapies have essentially made oligoprogression visible by holding most of the disease in check long enough for localized resistance to emerge on its own.

Detecting Oligoprogression

Accurate identification is the first practical hurdle. If your scans miss a growing lesion, what looks like oligoprogression could actually be more widespread disease, and treating only the visible spots would not help. Both CT scans and PET/CT are considered appropriate tools for assessing oligoprogression. Expert consensus supports using either modality, with the large majority of surveyed specialists agreeing that both are suitable.

³

That said, PET/CT appears to pick up oligoprogression more often than conventional imaging alone, particularly in lung cancer patients on targeted drugs. One study found that PET/CT identified oligoprogressive disease in about 63% of patients, compared with 35% when only conventional imaging was used. Patients whose oligoprogression was caught by PET/CT also had longer survival after progression than those with more widespread disease.

⁴

PET/CT may also detect lesions in locations that CT misses, such as bone or lymph nodes, which tend to behave more indolently. In one analysis, patients whose oligoprogression was found by PET/CT had a median time to further progression of about 333 days, compared with 143 days for those identified by CT alone.

⁵

Liquid Biopsy as a Risk-Stratification Tool

Beyond imaging, blood-based tests are emerging as a way to gauge how dangerous a patient’s oligoprogression really is. A liquid biopsy looks for fragments of tumor DNA circulating in the bloodstream. Among patients with oligoprogressive lung cancer who had liquid biopsies, about 56% tested positive for circulating tumor DNA. Those who tested positive had substantially worse outcomes: a median time before further progression of roughly 5 months, compared with nearly 12 months for those who tested negative.

⁶

This suggests that not all oligoprogression is created equal. A patient with a couple of growing spots on a scan but no detectable tumor DNA in their blood may have a truly localized problem worth treating aggressively with focal therapy. A patient with circulating tumor DNA may be closer to systemic resistance, even if imaging still looks limited. Liquid biopsy is not yet standard practice in this setting, but it is increasingly studied as a decision-making aid.

The Core Treatment Strategy: Focused Radiation

The leading approach to treating oligoprogressive lesions is stereotactic body radiation therapy, commonly called SBRT or SABR. This technique delivers very high doses of radiation to a small, precisely targeted area over just a few treatment sessions, sometimes even a single session. The goal is to destroy the growing lesion while leaving the patient on the same systemic therapy that is still controlling everything else.

The most important randomized evidence comes from the CURB trial, which enrolled patients with oligoprogressive breast cancer or non-small cell lung cancer and randomly assigned them to standard care alone or standard care plus SBRT to the progressing sites. The SBRT group had a median progression-free survival of about 7 months, compared with about 3 months for standard care alone, a statistically significant difference.

⁷

That trial represents the kind of head-to-head comparison the field has been waiting for, and while it is a phase 2 study rather than a definitive phase 3, it provides the strongest available evidence that zapping the rogue tumors actually buys meaningful time.

Evidence Across Different Cancer Types

Oligoprogression has been studied most extensively in lung cancer, but the concept and the treatment strategy span a growing list of tumor types. The evidence varies in maturity from one cancer to the next.

Lung Cancer

Non-small cell lung cancer with driver mutations is where the story began. A landmark retrospective study from 2012 first showed that local ablative therapy combined with continued targeted drugs could extend disease control. Patients with ALK-positive tumors who received local treatment had a median progression-free survival of about 9 months; for those with EGFR mutations, it was nearly 14 months.

⁸

More recent real-world data reinforce the approach. In a study of patients with EGFR-mutated lung cancer treated with radiotherapy plus continued targeted therapy, median overall survival reached nearly 22 months, and the authors emphasized that treatment should be initiated promptly once oligoprogression is identified.

⁹

Prostate Cancer

In prostate cancer, oligoprogression commonly occurs in men on hormone-suppressing drugs. The TRAP trial, a prospective study of SBRT for oligoprogressive prostate cancer under androgen suppression, reported a median progression-free survival of about 6 months. Roughly 55% of patients remained progression-free at six months and 39% at one year.

¹⁰

A phase 2 trial focusing on the prostate cohort found that at one year, about 55% of patients remained on the same systemic therapy line, and local control of the treated lesions was 84%.

¹¹

Even small case series support the approach. In a report of 11 consecutive prostate cancer patients treated with SBRT to oligoprogressive bone and lymph node sites, all patients achieved local control at their treated lesions, and 9 of 11 had a measurable drop in PSA levels.

¹²

Kidney Cancer

Renal cell carcinoma is another area where oligoprogression management is gaining ground. In a phase 2 study of patients with metastatic kidney cancer who developed oligoprogression on first-line systemic therapy, SBRT achieved a local control rate of about 97%, and median progression-free survival was 15 months.

¹³

A separate multicenter retrospective study of kidney cancer patients on combination immunotherapy and targeted therapy found similarly encouraging results. After two years, the overall response rate was 90%, and no severe radiation-related side effects above a mild grade were observed.

¹⁴

Breast Cancer and Liver Cancer

In breast cancer, the RADIANT trial examined SBRT for oligoprogressive disease and reported a median progression-free survival of about 20 months, with roughly 57% of patients still progression-free at one year.

¹⁵

For liver cancer, a multicenter phase 2 trial of patients with oligoprogressive hepatocellular carcinoma treated with continued first-line therapy plus focused radiation found a median progression-free survival of 7 months, with about 64% of patients progression-free at six months.

¹⁶

Should Systemic Therapy Be Continued or Switched?

This is one of the most practical questions patients and oncologists face. If a few tumors are growing on your current drug, does that mean the drug has failed and you should switch, or should you keep the drug and just blast the rogue spots? The evidence so far leans toward the latter for true oligoprogression, though it is not absolute.

A study that directly compared patients who switched systemic therapy after SBRT versus those who stayed on the same regimen found no meaningful difference in survival or time to the next treatment line. Median overall survival was about 32 months in the switch group and 38 months in the continuation group, with no statistically significant difference.

¹⁷

The practical implication is that if local treatment can address the progressing lesions, there is no rush to change drugs. This matters because patients have only a limited number of effective systemic therapy lines available to them over their lifetime. Burning through a drug line prematurely when only a few spots are misbehaving wastes a therapeutic option that might be badly needed later. The idea of delaying the switch is especially relevant in cancers like gastric cancer, where no prospective trial has yet proven that local treatment during oligoprogression improves survival, but experts suggest it can delay the next systemic line, control symptoms, and preserve quality of life.

¹⁸

Surgery as an Alternative to Radiation

While SBRT gets most of the attention, surgery is another way to deal with oligoprogressive lesions, particularly when a tumor is in a location where radiation is difficult or when tissue is needed for molecular analysis. In kidney cancer, for instance, removing a progressing metastasis can provide both disease control and a tissue sample that reveals new resistance mutations, which may guide the next treatment choice. Complete surgical removal of progressing metastases has been associated with a survival benefit in selected patients.

¹⁹

Surgery is not always straightforward in this setting, though. These patients have metastatic cancer and are often on systemic therapies that carry their own side effects. The complication rates from surgery are not trivial, and international guidelines emphasize that careful patient selection is critical. Surgery tends to be considered when a lesion is accessible, when the patient is fit enough for the procedure, or when the tumor’s molecular profile needs to be reassessed from actual tissue rather than a blood test.

Safety of Combined Radiation and Systemic Therapy

A reasonable concern is whether piling radiation on top of targeted drugs or immunotherapy creates dangerous side effects. The existing data are reassuring, though not without nuance. A systematic review of severe toxicity when focused radiation was combined with targeted therapy found that serious side effects directly related to the radiation occurred in roughly 5 to 8% of patients for cranial treatments and about 8 to 9% for treatments outside the brain. Overall, severe radiation-related toxicity was lower for brain-directed treatment (about 6%) compared with radiation to other body sites (about 9%).

²⁰

When it comes to combining liver-directed SBRT with immunotherapy specifically, one study found that the rate of liver-related side effects was essentially the same whether patients received radiation to their liver metastases or not, at about 10 to 11%. The toxicity was largely driven by the immunotherapy regimen itself rather than the radiation.

²¹

An international expert consortium from EORTC and ESTRO has published consensus recommendations specifically addressing the safety of combining metastasis-directed SBRT with targeted therapy or immunotherapy, reflecting the growing confidence that these combinations are manageable for most patients.

²²

What Happens After Treatment

Treating oligoprogressive lesions buys time, but the disease is not cured. The most common pattern after SBRT for oligometastatic disease is the development of new distant metastases rather than regrowth of the treated spots. In one large analysis, the rate of local failure at the irradiated site was only about 4% at one year, while new distant metastases appeared in roughly 45% of patients over the same period.

²³

Some patients go through this cycle more than once, receiving repeat rounds of SBRT as new lesions emerge. A study of patients who underwent repeat SBRT found that these individuals tended to develop new metastases at a slower rate, about 0.5 new lesions per month, compared with 1.0 per month in patients treated with only a single course. This slower pace of progression may itself be a sign that the underlying disease biology is more favorable in people who keep presenting with limited recurrences.

²⁴

The Immunotherapy Wrinkle

An intriguing possibility with oligoprogression treated during immunotherapy is the abscopal effect, where radiation to one tumor triggers the immune system to attack untreated tumors elsewhere. In a small study of patients with solid tumors experiencing oligoprogression on checkpoint inhibitors, half showed evidence of abscopal responses at sites that were not irradiated. The median time from radiation to confirmation of these distant responses was about four months. All three patients with strongly positive PD-L1 expression experienced abscopal effects, while none of the PD-L1-negative patients did.

²⁵

This is a small and preliminary finding, but it points to something genuinely exciting: in the immunotherapy setting, treating the rogue lesion might not just remove the problem spot but actively boost the immune response against remaining disease. Whether this holds up in larger studies is one of the open questions in the field.

Cost and Access Considerations

SBRT is a relatively expensive technology that requires specialized equipment and expertise. A cost-effectiveness analysis of SABR (the same treatment under a slightly different name) for oligometastatic disease found that it was cost-effective by conventional standards. The treatment added about 0.78 quality-adjusted life-years over the trial period and 1.34 over the long term, with only a marginal increase in total costs. The incremental cost-effectiveness ratio was under $39,000 per quality-adjusted life-year in the long-term analysis, well below the thresholds typically used to define good value.

²⁶

The practical access problem is that SBRT is concentrated at academic medical centers and specialized cancer hospitals. Patients treated in community settings may not have their oligoprogression recognized as such, or may not be offered local treatment even when it is appropriate. Delaying the next line of systemic therapy has financial implications too. Newer cancer drugs are extraordinarily expensive, and every month a patient can stay on a working regimen instead of escalating to a costlier next-line drug represents savings for the patient and the healthcare system. Researchers have argued that time to next systemic therapy line should be recognized as a meaningful clinical endpoint in trials, partly because it correlates with quality of life and partly because it captures a dimension of benefit that traditional survival measures can miss.

²⁷

Toward Genomically Guided Radiation Dosing

One of the frontiers in this space is personalizing not just whether to radiate, but how much radiation to deliver, based on the tumor’s genetics. A concept called the genomic adjusted radiation dose uses the expression of a small panel of genes to estimate how sensitive a given tumor is to radiation. A higher score suggests the tumor will respond more strongly to treatment. This model has been validated across several cancer types and could eventually allow oncologists to tailor radiation doses to individual patients rather than relying on one-size-fits-all schedules.

²⁸

Pairing genomic profiling with liquid biopsy data and advanced imaging could eventually create a much more precise picture of who benefits from local treatment at oligoprogression, who needs a therapy switch, and who falls somewhere in between. For now, the field relies largely on imaging and clinical judgment, but the toolkit is expanding rapidly.